Word: squibb
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
Ebert will meet with the other group-made up of third year students-today to discuss the same questions. Ebert said last night that he is "perfectly prepared to resign" from the Squibb board, but that he wants a chance to talk with students and explain his situation first...
...groups of medical students have appeared in the last few days to ask Dr. Robert H. Ebert, the Med School dean, to give up his seat on the board of Squibb-Beech-Nut Inc., makers of Squibb pharmaceuticals...
There are no charges of financial impropriety. When Ebert became a director last January, he owned about $15,000 worth of Squibb-Beech-Nut stock and was eligible for a yearly salary of several thousand dollars as a director...
Over the summer, Ebert decided that the arrangement might give the appearance of a conflict. He says he tried to resign from the board, and finally agreed to stay on as a "public" director. He sold all his Squibb stock and no longer has any personal financial interest in the company's performance...
...decisive action, it has run into strong opposition. The agency is trying to remove from the market 1) a combination of two antibiotics, tetracycline and novobiocin, marketed by the Upjohn Co. as Panalba, and 2) a combination of tetracycline with an antifungal agent, sold as Mysteclin-F (E. R. Squibb & Sons), Declostatin (Lederle Laboratories) and Tetrastatin (J. B. Roerig division of Chas. Pfizer & Co. Inc.). Upjohn has already taken its case to the courts, and the other firms may do so as well. Both drugs are widely prescribed items, ringing up tens of millions in annual sales. Panalba and related...